Search Results
Your search for ,aGe matches 8736 pages
Showing 6051 - 6100Dutch Study Shows Increased Risk of Second Cancer for Survivors of Hodgkin Lymphoma During Long-Term Follow-up
In a Dutch study reported in The New England Journal of Medicine, Schaapveld et al found that survivors of Hodgkin lymphoma treated between 1965 and 2000 were at a 4.6-fold greater risk of second cancer vs the general population during long-term follow-up. There was no significant difference in the ...
Study Examines Evolution of Cancer
A novel Yale University study answers age-old questions about how cancers spread by applying tools from evolutionary biology. The new insights will help scientists better understand the genetic origins of tumor metastases, and lead to more effective targets for treatment, said the researchers. The...
Interruption of Radiation Therapy Due to Noncompliance Risks Cancer Recurrence
Cancer patients who miss two or more radiation therapy sessions (except for planned treatment breaks) have a worse outcome than fully compliant patients, investigators at Montefiore Einstein Center for Cancer Care (MECCC) and Albert Einstein College of Medicine's Albert Einstein Cancer Center have...
Study Finds Enzalutamide Increases Progression-Free Survival vs Bicalutamide in Metastatic Prostate Cancer
Use of the androgen receptor–inhibitor enzalutamide (Xtandi) more than doubled progression-free survival vs the nonsteroidal antiandrogen bicalutamide in patients with metastatic prostate cancer progressing on androgen-deprivation therapy, according to the randomized phase II TERRAIN trial...
ACS/ASCO Breast Cancer Survivorship Care Guideline
The American Cancer Society (ACS) and ASCO have issued a Breast Cancer Survivorship Care guideline, published jointly in the Journal of Clinical Oncology and CA: A Cancer Journal for Clinicians. The guideline recommendations were formulated by a multidisciplinary expert work group and are based on...
Study Finds Time Lag Between Positive Fecal Blood Test and Follow-up Colonoscopy
Annual testing for blood in the stool using high-sensitivity guaiac fecal occult blood tests or fecal immunochemical tests is one of several recommended colorectal cancer screening strategies for adults 50 to 70 years old. However, although a positive finding requires a follow-up colonoscopy to...
Reduction in Late Mortality in Childhood Cancer Survivors in the Childhood Cancer Survivor Study Cohort
In a study reported in The New England Journal of Medicine, Armstrong et al found that late mortality decreased over time among 5-year survivors of childhood cancer in the Childhood Cancer Survivor Study cohort. The reduction is consistent with efforts during recent decades to modify treatment with ...
Possible Marker for Recurring HPV-Linked Oropharyngeal Cancers
A retrospective analysis of human papillomavirus (HPV) antibodies in patients treated for oropharyngeal cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, said scientists at The Johns Hopkins...
Alectinib in ALK-Positive Metastatic NSCLC After Crizotinib
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On December 11, 2015, alectinib (Alecensa) was granted...
Immunotherapy Expert Crystal Mackall, MD, Joins Stanford Medicine Faculty
Cancer immunotherapy expert Crystal Mackall, MD, joined the Stanford University School of Medicine faculty on January 1 as Professor of Pediatrics and Medicine, as well as Associate Director of the Stanford Cancer Institute and Co-Medical Director of the Stanford Laboratory for Cell and Gene...
Removal of Complex Renal Tumors Performed Safely by Robotic Surgery in Selected Patients
Renal cell carcinoma can sometimes spread to the inferior vena cava, posing a threat to the heart and brain. Robotic nephrectomy for inferior vena cava tumor thrombus has favorable outcomes in selected patients compared with open surgery, which can have a high rate of complications, reported Abaza...
New AJCC Precision Medicine Guidelines Aimed at Improving Personalized Cancer Treatment Plans for Patients
A committee of national experts, led by a Cleveland Clinic researcher, has established first-of-its-kind guidelines to promote more accurate and individualized cancer predictions, guiding more precise treatment and leading to improved patient survival rates and outcomes. These guidelines were...
Selected Abstracts From 2015 ASH Annual Meeting: Part 2
Here are several more abstracts selected from the proceedings of the 2015 American Society of Hematology (ASH) Annual Meeting and Exposition, highlighting therapeutics in acute leukemias and myelodysplastic syndromes. For five other top abstracts on therapies for acute leukemias and myelodysplastic ...
Expanded Approval of Pembrolizumab in Unresectable or Metastatic Melanoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On December 18, 2015, approval of the programmed cell death...
A Pioneering Oncologist’s Roadmap Forward
Bookmark Title: The Death of Cancer: After Fifty Years on the Front Lines of Medicine, a Pioneering Oncologist Reveals Why the War on Cancer Is Winnable—and How We Can Get There Authors: Vincent T. DeVita, Jr, MD, and Elizabeth DeVita-Raeburn Publisher: Farrar, Straus and Giroux Publication date:...
FDA Approves Ofatumumab for Patients With Chronic Lymphocytic Leukemia in Complete or Partial Response
The U.S. Food and Drug Administration (FDA) has approved ofatumumab (Arzerra), a CD20-directed cytolytic monoclonal antibody, for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia...
How Cancer and Its Treatments Affect Cognitive Function
Although chemotherapy is often cited as the main culprit for diminishing cognitive function in patients with cancer, ushering the term “chemobrain” into the vernacular, research by Tim A. Ahles, PhD, and his colleagues is showing that multiple factors may contribute to the condition.1 Using breast...
Increased Incidence of in Situ and Invasive Melanoma in Denmark
In a study reported in JAMA Dermatology,1 Neel Maria Helvind, MD, of the University Hospital Rigshospitalet, Copenhagen, Denmark, and colleagues analyzed the increases in melanoma incidence seen in Denmark between 1985 and 2012. Over that time, the incidence of malignant melanoma doubled to rates...
Transcription Factor CDX2 May Be Prognostic Biomarker in Stage II and III Colon Cancer
In a study reported in The New England Journal of Medicine, Dalerba et al found that absence of the transcription factor CDX2, although prognostic for poor outcome in stage II and III colon cancer vs cancers with CDX2 expression, identified a subgroup of high-risk patients who appeared to benefit...
Increased Survival and Toxicity With Docetaxel, No Apparent Benefit of Zoledronic Acid in Prostate Cancer
As reported in The Lancet by James et al, results of the STAMPEDE trial, which used a multiarm, multistage seamless phase II/III design, showed increased survival and toxicity with docetaxel and little benefit of zoledronic acid when added to first-line long-term hormone therapy in patients with...
Bone Loss Associated With Leukemia Therapy Occurs Sooner Than Previously Thought
Investigators at Children’s Hospital Los Angeles (CHLA) have found that significant bone loss occurs during the first month of chemotherapy for acute lymphoblastic leukemia (ALL), which is far earlier than previously assumed. Results of the study were published by Orgel et al in the...
Superior Long-Term Outcomes Linked to Axillary Pathologic Complete Response After Chemotherapy for Breast Cancer
In an analysis of experience at MD Anderson Cancer Center reported in JAMA Oncology, Mougalian et al found that 10-year overall and relapse-free survival rates in patients with stage II or III breast cancer and axillary metastases receiving primary systemic chemotherapy were higher in those with vs ...
World Cancer Day 2016: We Can. I Can.
Cancer will kill more than 8 million people worldwide this year, which is equivalent to the entire population of New York. Half of these will be people of working age (30–69 years old). It has been estimated that the cost implications on world economies caused by cancer and the other...
For Postmenopausal Women With Ductal Carcinoma in Situ: NSABP B-35 and IBIS-II DCIS Trials Offer a Choice of Endocrine Therapy
The past year has produced an embarrassment of riches regarding the value of aromatase inhibitors for women with ductal carcinoma in situ of the breast. The long-awaited NSABP B-35 study matured and was reported by Margolese and colleagues at the 2015 ASCO Annual Meeting this past summer, followed...
Comparing Recurrence Risk With Anastrozole vs Tamoxifen in Postmenopausal Women With Ductal Carcinoma in Situ
Two recently reported phase III trials compared adjuvant anastrozole vs tamoxifen in postmenopausal women with hormone receptor–positive ductal carcinoma in situ. As reported in The Lancet by Margolese et al,1 the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-35 trial, performed in...
Expert Point of View: C. Kent Osborne, MD
These data will help us personalize treatment for our patients. We still don’t know which women with a favorable cancer like ductal carcinoma in situ are most likely to progress. This is an unmet need,” said C. Kent Osborne, MD, Director of the Dan L. Duncan Cancer Center at Baylor College of...
Tamoxifen or Anastrozole for Ductal Carcinoma in Situ?
Ductal carcinoma in situ is a relatively benign form of breast cancer (stage 0), yet up to 10% of women with ductal carcinoma in situ will have a recurrence within 10 years. At present, there is no way to identify which women will recur, so standard treatment is lumpectomy plus radiation therapy....
Selected Abstracts From 2015 San Antonio Breast Cancer Symposium
The 2015 San Antonio Breast Cancer Symposium (SABCS), hosted by the American Association for Cancer Research, the Cancer Therapy & Research Center at The University of Texas Health Sciences Center at San Antonio, and Baylor College of Medicine, was held in December 2015. As has been true for...
Atezolizumab in Urothelial Cancer: Ushering in a New Standard of Care
Atezolizumab achieved excellent results in a cohort of patients with platinum-resistant urothelial cancer enrolled in a large phase II trial known as IMvigor 210.1 Overall response rates were greatly improved over those with historical controls, and responses were durable. Although expression of...
Improved Outcomes in Patients With Germ Cell Testicular Tumors in the Modern Era
Although patients with poor-risk metastatic testicular germ cell tumors continue to have less favorable outcomes, the bar has been raised by contemporary treatment. There is still room for improvement in managing metastatic testicular germ cell tumors, especially in poor-risk patients, but if...
Cancer Registries and the Evolving Role of Big Data in Cancer Care
In 1956, the American College of Surgeons encouraged the development of hospital-based registries, but for the most part, these efforts were clumsy, inaccessible card files of data. Today, advanced microcomputer technology has increased the ability to not only collect and cull cancer data but also...
Higher Risk of Cancer Mortality in Solid-Organ Transplant Recipients
In a study reported in JAMA Oncology, Acuna et al found a nearly threefold increased risk of cancer mortality in solid-organ transplant recipients compared with the general population in Ontario, Canada. Study Details The population-based cohort study included data from 11,061 patients who...
Study Finds Association Between Androgen-Deprivation Therapy in Prostate Cancer and Risk of Alzheimer’s Disease
In a retrospective analysis reported in the Journal of Clinical Oncology, Nead et al found that use of androgen-deprivation therapy in the treatment of prostate cancer was associated with an increased risk of subsequent Alzheimer’s disease. Study Details In the study, a text-processing...
Many Americans Favor a Tax Increase to Support the 'Moonshot' Cancer Initiative
Vice President Joe Biden's “moonshot” initiative to defeat cancer earned support for a tax increase to fund cancer research among half of respondents (50%) in a new national public opinion survey commissioned by Research!America. Thirty-eight percent disagree and an additional 12% are...
French Trial Shows Addition of First-Line Bevacizumab to Cisplatin/Pemetrexed Improves Survival in Malignant Pleural Mesothelioma
In the French phase III MAPS trial reported in The Lancet, Zalcman et al found that the addition of bevacizumab (Avastin) to standard cisplatin/pemetrexed (Alimta) treatment increased overall and progression-free survival in patients with newly diagnosed pleural mesothelioma. Vascular endothelial...
Material and Psychological Financial Hardship for U.S. Cancer Patients
In a population-based study reported in the Journal of Clinical Oncology, Yabroff et al found that cancer and its treatment were associated with material financial hardship for 29% and psychological financial hardship for 32% of patients aged 18 to 64 years in the United States. Financial hardship...
Increased Breast Cancer Risk Reported in Childhood Sarcoma and Leukemia Survivors With No History of Chest Radiotherapy
In an analysis of the Childhood Cancer Survivor Study reported in the Journal of Clinical Oncology, Henderson et al found that childhood survivors of sarcoma and leukemia with no history of chest radiotherapy were at an increased risk of breast cancer. Increased Risk The study included data from...
UK Study Finds No Association Between Self-Reported Unhappiness and Mortality Risk
As reported in The Lancet by Liu et al, a study in UK women that attempted to adjust for the effect of health and lifestyle factors found that self-reported unhappiness was not associated with an increased risk of mortality from cancer or other conditions. Study Details The study involved data...
USPSTF Recommendation Confirms Value of Screening Mammography
The recently updated U.S. Preventive Services Task Force (USPSTF) recommendation once again confirmed the value of screening mammography, concluding that the benefit of mammography outweighs the harms of screening in all age groups from age 40 through age 74. It emphasizes that both women and...
Famed Cancer Biostatistician, Norman Breslow, PhD, Dies
A longitudinal case-controlled analysis of the probability of attaining normality after achieving 60: A perspective from the social sciences based on expert ethnographic insights.” So begins a long and charmingly erudite birthday card to internationally regarded biostatistician Norman Breslow, PhD, ...
Nationally Regarded Cancer Advocate Ellen Stovall Dies
Passion is a much-needed virtue in one who seeks to change the world for the better. When you combine intelligence, stamina, iron-willed determination, the grace of an ambassador, and simple human likability with passion, you get that rare person who can turn words and ideas into reality. Such a...
Expect Questions About Ovarian Cancer Screening
The authors of an ovarian cancer screening study published in The Lancet1 and many of the experts commenting on the study in the media agree that the results of multimodal screening are encouraging and could reduce mortality from ovarian cancer, but further follow-up is needed. Considering that the ...
Could a Screening Test That Would Reduce Deaths From Ovarian Cancer Be on the Way?
"A solid triple but not a home run” is how Karen H. Lu, MD, characterized a study in The Lancet reporting a reduction in deaths from ovarian cancer with the use of multimodal ovarian cancer screening.1 Dr. Lu’s remark was one of several, mostly but not universally, favorable and optimistic comments ...
Mastectomy Healed by Earth Dressing
Through the Lens of Oncology History A Century of Progress The text and photographs on this page are excerpted from a four-volume series of books titled Oncology Tumors & Treatment: A Photographic History, by Stanley B. Burns, MD, FACS. The photos below are from the volume titled “The...
Pieces of Grief
The ASCO Post is pleased to reproduce installments of the “Art of Oncology” as published previously in the Journal of Clinical Oncology (JCO). These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
A Noted Breast Surgeon’s Book of Solid Advice
Bookmark Title: The New Generation Breast Cancer Book: How to Navigate Your Diagnosis and Treatment Options—and Remain Optimistic—in an Age of Information Overload Author: Elisa Port, MD Publisher: Ballantine Books Publication date: September 2015 Price: $20.00; paperback, 320 pages When a new...
Cancer Incidence in Indigenous People in Australia, New Zealand, Canada, and the United States
In a population-based study reported in The Lancet Oncology, Suzanne P. Moore, PhD, of Charles Darwin University, Northern Territory, Australia, and colleagues compared cancer incidence in indigenous people in Australia, New Zealand, Canada, and the United States with the incidence in nonindigenous ...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Afghanistan
The ASCO Post is pleased to introduce this special focus on the worldwide cancer burden, beginning in this issue with a close look at the cancer incidence and mortality rates in the United States. The aim of this special feature is to highlight the global cancer burden for various countries of the...
Ibrutinib in Relapsed Mantle Cell Lymphoma
Treatment of mantle cell lymphoma continues to evolve, both in the front-line and relapsed settings. Key advances include better use of established agents, such as the incorporation of high-dose cytarabine into initial induction regimens and application of rituximab (Rituxan)...
Phase III Trial Shows Improved Progression-Free Survival With Ibrutinib vs Temsirolimus in Relapsed/Refractory Mantle Cell Lymphoma
In aphase III trial reported in The Lancet and at the recent American Society of Hematology Annual Meeting and Exposition, Martin Dreyling, MD, of the European Mantle Cell Lymphoma Network, and colleagues found that ibrutinib (Imbruvica) was associated with improved progression-free survival vs...
